CALR and essential thrombocythemia: VAT1L is mainly expressed in the brain and CALR mutation status defined subtypes of essential thrombocythemia with substantially different clinical course and outcomes, thus it could be a potential biomarker for myeloproliterative neoplasm [44, 45].